| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: =98.40%
| Targets |
Desmopressin Acetate targets the vasopressin V2 receptor in the kidney. By acting as a V2 receptor agonist, it increases cellular permeability in the distal kidney tubule, leading to water reabsorption and antidiuretic effects. It also increases circulating factor VIII and is used in patients with hemophilia and von Willebrand's disease.
|
|---|---|
| ln Vitro |
In vitro, Desmopressin Acetate is a vasopressin analogue with selective affinity for the V2 receptor. It is used in cell-based assays to study vasopressin receptor signaling and water transport. Its activity is related to its ability to stimulate water reabsorption.
|
| ln Vivo |
In vivo, Desmopressin Acetate exhibits antidiuretic activity and is useful in improving cardiocirculatory functions. It acts on the distal kidney tubule by increasing cellular permeability, thereby stimulating water reabsorption. It also increases circulating factor VIII and is used in patients with hemophilia and von Willebrand's disease.
|
| Enzyme Assay |
In vitro receptor binding assays for Desmopressin Acetate typically involve measuring its affinity for the vasopressin V2 receptor. The compound is incubated with cells expressing the receptor, and binding is quantified. Functional assays, such as measuring cAMP production upon receptor activation, are also used to confirm its agonistic activity.
|
| Cell Assay |
Cell culture protocols for Desmopressin Acetate involve treating cells expressing the V2 receptor with the compound at varying concentrations. The effects on cell signaling and water transport are then assessed. The peptide is dissolved in a suitable solvent and added to the culture medium.
|
| Animal Protocol |
In vivo animal study protocols for Desmopressin Acetate would depend on the specific research question. It is used as a therapeutic agent for conditions like diabetes insipidus and hemophilia. In research, it could be administered to animal models to study its antidiuretic and hemostatic effects.
|
| ADME/Pharmacokinetics |
Desmopressin Acetate has a molecular weight of 1189.3 g/mol, a formula of C46H64N14O12S2·2C2H4O2, and a CAS number of 16789-98-3. It is typically stored as a powder at -20°C and is soluble in water and methanol.
|
| Toxicity/Toxicokinetics |
Toxicological data for Desmopressin Acetate is not extensively reported in the provided sources. As a therapeutic agent, its safety profile has been established in clinical use. Standard safety precautions should be observed in research settings.
|
| Additional Infomation |
Desmopressin acetate is an analogue of vasopressin, possessing antidiuretic and hemostatic effects. Desmopressin acetate has a selective affinity for V2 receptors, acting on the distal renal tubules to stimulate water reabsorption by increasing cell permeability. This antidiuretic is used to treat central diabetes insipidus. Another effect of desmopressin acetate is to increase circulating factor VIII levels, used to treat hemophilia and von Willebrand disease. Arginine vasopressin is a synthetic analogue of a pituitary hormone. Its action is mediated by the vasopressin receptor V2. It has sustained antidiuretic activity but a small pressor effect. It can also regulate circulating factor VIII and von Willebrand factor levels. See also: Desmopressin (with active moiety).
Desmopressin Acetate has a CAS number of 16789-98-3. It is a synthetic analogue of vasopressin with antidiuretic and antihemorrhagic properties. It is used clinically to treat diabetes insipidus, hemophilia, and von Willebrand's disease. It is also used in research. |
| Molecular Formula |
C50H72N14O16S2
|
|---|---|
| Molecular Weight |
1189.3209
|
| Exact Mass |
1128.448
|
| CAS # |
16789-98-3
|
| Related CAS # |
16679-58-6 (Parent);Desmopressin;62288-83-9
|
| PubChem CID |
9833407
|
| Sequence |
Mpr-YFQNCP-(D-R)-G-NH2（Disulfide Bond Between Mpr and Cys6)
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.56 g/cm3
|
| LogP |
1.705
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
78
|
| Complexity |
2070
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
S1C([H])([H])C([H])(C(N2C([H])([H])C([H])([H])C([H])([H])C2([H])C(N([H])C([H])(C(N([H])C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)=O)N([H])C(C([H])(C([H])([H])C(N([H])[H])=O)N([H])C(C([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)N([H])C(C([H])(C([H])([H])C2C([H])=C([H])C([H])=C([H])C=2[H])N([H])C(C([H])(C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])O[H])N([H])C(C([H])([H])C([H])([H])S1)=O)=O)=O)=O)=O.O([H])C(C([H])([H])[H])=O.O([H])C(C([H])([H])[H])=O
|
| InChi Key |
MLSVJHOYXJGGTR-IFHOVBQLSA-N
|
| InChi Code |
InChI=1S/C46H64N14O12S2.C2H4O2/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4)/t28-,29+,30+,31+,32+,33+,34+;/m1./s1
|
| Chemical Name |
acetic acid;(2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8408 mL | 4.2041 mL | 8.4082 mL | |
| 5 mM | 0.1682 mL | 0.8408 mL | 1.6816 mL | |
| 10 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA